Literature DB >> 24413303

Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis.

Reynald Lescarbeau1, David L Kaplan.   

Abstract

Prostate cancer most commonly presents as initially castration dependent, however in a minority of patients the disease will progress to a state of castration resistance. Here, approaches for correlating alterations in the phosphoproteome with androgen independent cell survival in the LNCaP, PC3, and MDa-PCa-2b cell lines are discussed. The performance of the regression techniques multiple linear, ridge, principal component, and partial least squares regression is compared. The predictive performance of these algorithms over randomized data sets and using the Akaike Information Criterion is explored, and principal component and partial least squares regression are found to outperform other regression approaches. The effect of altering the number of features versus observations on the R(2) value and predictive performance is also examined using the partial least squares regression model. Utilizing these approaches "drivers" of castration resistant disease can be identified whose modulation alters phenotypic outcomes. These data provide an empirical comparison of the various considerations when statistically analyzing phosphorylation data with the aim of correlating with phenotypic outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24413303      PMCID: PMC3967742          DOI: 10.1039/c3mb70403c

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  19 in total

1.  Systems biology and combination therapy in the quest for clinical efficacy.

Authors:  Jonathan B Fitzgerald; Birgit Schoeberl; Ulrik B Nielsen; Peter K Sorger
Journal:  Nat Chem Biol       Date:  2006-09       Impact factor: 15.040

2.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Meng Sun; Jun Chen; Jiao Yue; Hsing-Jien Kung; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

3.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

4.  Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

Authors:  Amina Zoubeidi; Anousheh Zardan; Romina M Wiedmann; Jennifer Locke; Eliana Beraldi; Ladan Fazli; Martin E Gleave
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

Review 5.  Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

6.  Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.

Authors:  Gang Wang; Jun Wang; Marianne D Sadar
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

7.  Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.

Authors:  Soo Ok Lee; Wei Lou; Candace S Johnson; Donald L Trump; Allen C Gao
Journal:  Prostate       Date:  2004-08-01       Impact factor: 4.104

Review 8.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

9.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Authors:  Carolyn Waugh Kinkade; Mireia Castillo-Martin; Anna Puzio-Kuter; Jun Yan; Thomas H Foster; Hui Gao; Yvonne Sun; Xuesong Ouyang; William L Gerald; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

10.  A predictive phosphorylation signature of lung cancer.

Authors:  Chang-Jiun Wu; Tianxi Cai; Klarisa Rikova; David Merberg; Simon Kasif; Martin Steffen
Journal:  PLoS One       Date:  2009-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.